Vnitr Lek 2024, 70(5):314-317 | DOI: 10.36290/vnl.2024.062

Arterial hypertension - chronic disease which needs an active and dynamic approach

Pavel Rutar
Interní oddělení Nemocnice Na Homolce, Praha

Cardiovascular diseases are 80 % preventable. One of the main risk factors of cardiovascular diseases which can be controlled easily is arterial hypertension. There are two main conditions which influences our chance to reach the therapeutic target - active role of a physician and a patient's adherence to the therapy. Early treatment, the proper choice of the drug, periodic check-up of results and fortification of the therapy if it's necessary, encouraging patient's adherence by a simple therapeutic schema with using a polypill and a control of other important cardiovascular risk factors as hypercholesterolaemia - these are characteristics which bring us the biggest cardiovascular risk reduction.

Keywords: arterial hypertension, therapeutic inertia, adherence, fix combination, polypill, ACE inhibitors.

Accepted: August 28, 2024; Published: September 4, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rutar P. Arterial hypertension - chronic disease which needs an active and dynamic approach. Vnitr Lek. 2024;70(5):314-317. doi: 10.36290/vnl.2024.062.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vital Signs: Preventing 1 Million Heart Attacks and Strokes. [cit. 2023-02-17]. Available from .
    2. Dalia A. Therapeutic inertia in the management of hypertension in primary care. J Hypertens. 2021 39(6):1238-1245. Go to original source... Go to PubMed...
    3. Václavík J. Kombinační léčba jednou tabletou - budoucnost léčby hypertenze? Interní Med. 2014;16(6):228-230.
    4. Widimský J, et al. Doporučení ČSH 2022. Hypertenze a KV prevence. 2022;12:1-25.
    5. Widimský J. jr. Trojkombinace v léčbě hypertenze. Kardiol Rev Int Med. 2014;16(6):449-453.
    6. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. Go to original source... Go to PubMed...
    7. Gupta A, et al. Long term benefits of blood pressure treatment on the incidence of atrial fibrillation, heart failure and cardiovascular morbidity and mortality: 20-years follow-up of ASCOT-Legacy. J Hypertens. 2021;39 (e-Supplement 1). Go to original source...
    8. Bertrand ME, Ferrari R, Remme WJ, et al. Clinical synergy of perindopril and calcium channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J. 2010;159(5):795-802. Go to original source... Go to PubMed...
    9. Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study; PERTINENT. Cardiovasc Res. 2007;73:237-246. Go to original source... Go to PubMed...
    10. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert rev. Cardiovasc Ther. 2005;3:15-29. Go to original source... Go to PubMed...
    11. Kulkarni S., Graggaber J. How to improve compliance to hypertension treatment. E-Journal of Cardiology Practice. 2022;22:6-23.
    12. Koval S, et al. Efficacy of fixed dose of triple combination of perindopril-indapamide-amlodipine in obese patients with moderate-to-severe arterial hypertension: an open-label 6-month study. Biomed Res Ther. 2019;6(11):3501-3512. Go to original source...
    13. Telejko E, et al. Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril. Curr Med Res Opin. 2007;23:953-960. Go to original source... Go to PubMed...
    14. Študentová K. Triplixam v ordinaci praktického lékaře. Med. Praxi. 2015;12(5):261-262.
    15. Snyman JR, et al. A real-world analysis of outcomes and healthcare costs of patients on perindopril/indapamide/amlodipine single-pill vs. multiple-pill combination in Italy. J Hypertens. 2024;42(1):136-142. Go to original source... Go to PubMed...
    16. Gupta P, et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension. 2017,70:1042-1048. Go to original source... Go to PubMed...
    17. Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.